Myocholine

Quick links to important sections

Myocholine

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myocholine

What is Myocholine? (Bethanechol Chloride)

Property Description
Active Ingredient Bethanechol Chloride
Forms Oral Tablet, Subcutaneous Solution
Pharmacological Class Direct-Acting Muscarinic Receptor Agonist
Common Action Stimulates smooth muscle contraction (e.g., bladder, GI tract)
Origin Synthetic Ester

Myocholine is a prescription-only medication containing the active ingredient Bethanechol Chloride, a synthetic ester used to restore function in specific smooth muscles. Pharmacologically, it is classified as a parasympathomimetic agent, meaning it activates the system responsible for involuntary functions like digestion and urination.


What is Bethanechol Chloride and How is it Classified?

Bethanechol Chloride is chemically defined as a quaternary ammonium compound and a choline ester. This classification is key because the substance functions as a direct-acting muscarinic receptor agonist, meaning it directly activates the receptors typically responsive to the neurotransmitter acetylcholine. Its synthetic structure is a distinguishing factor, allowing it to resist breakdown by the enzyme cholinesterase, ensuring a therapeutically effective and prolonged duration of action in the body. This resistance to rapid metabolism is clinically recognized as vital for its application, particularly where sustained muscle activation is required.


What Forms Does Myocholine Come In?

The active substance is provided as a single-ingredient product in two main dosage forms: the oral tablet and a sterile solution for subcutaneous injection. The tablet allows for administration via the oral route, while the injectable solution is designated for use via the subcutaneous route in controlled clinical settings. The general purpose of this cholinergic agent is to increase tone and motility in smooth muscle tissues where function has become impaired. The medication is used to help facilitate natural bodily processes, such as promoting bladder emptying and restoring intestinal movement.

Regulatory References

  1. Bethanechol - StatPearls - NCBI Bookshelf

What side effects are possible with Myocholine?

Myocholine: Possible side effects and safety information

Official regulatory documentation structures the safety profile of Myocholine (Bethanechol Chloride) by classifying adverse reactions based on the affected system and administration route. The frequency of side effects is noted as rare following oral administration of the tablet, but they are more common following subcutaneous injection. Adverse reactions are also more likely to occur when the dosage is increased.


Documented Adverse Reaction Categories

Adverse effects are grouped into several System-Organ Classes (SOCs), reflecting the drug’s generalized muscarinic activity across smooth muscle tissues. The most frequently documented systems involved are the Digestive System (e.g., abdominal cramps, nausea, diarrhea, salivation), the Cardiovascular System (e.g., a fall in blood pressure, reflex tachycardia), and the Skin and Subcutaneous Tissue (e.g., flushing and sweating).

Serious Adverse Reactions and Restrictions

The label documents the potential for rare but serious adverse reactions, including pronounced bradycardia, severe hypotension, transient complete heart block, and seizures.

Furthermore, the regulatory text specifies several conditions that are contraindications—situations where the drug must not be used. These include pre-existing severe conditions such as active or latent bronchial asthma, pronounced bradycardia or hypotension, peptic ulcer, and coronary artery disease.


Population-Specific Safety Notes

The medicine's safety and effectiveness have not been established in pediatric patients. For pregnant individuals, the drug is categorized as Category C, meaning it should be administered only if clearly needed. Specific warnings also exist concerning the potential for serious adverse reactions in nursing infants.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Myocholine (Bethanechol Chloride) is characterized by severe muscarinic overstimulation, resulting in a predictable set of clinical manifestations. Officially documented symptoms include significant salivation, profuse sweating, flushing of the skin, nausea, vomiting, and severe abdominal cramps that may escalate to diarrhea.

The regulatory profile indicates that overdose can lead to serious and life-threatening systemic outcomes. These severe manifestations include a significant fall in blood pressure, potentially resulting in circulatory collapse, shock, and cardiac arrest. Respiratory function may also be severely compromised by the onset of severe bronchospasm.

Immediate medical attention is required for any suspected overdose. Emergency services must be contacted immediately if severe manifestations are noted, such as difficulty breathing, collapse, or seizure.

The prescribing information documents the existence of a specific antidote: Atropine sulfate. The immediate administration of this antidote is required to reverse the effects of the overstimulation, often utilizing the subcutaneous route as preferred in official guidelines. General supportive and symptomatic treatment must follow. A distinct, weight-based antidote dosage is specifically documented for use in pediatric patients.

Therapeutic Uses of Myocholine

Myocholine: Main Uses and Benefits

The medicine is primarily used to provide supportive symptomatic relief by addressing functional difficulties associated with certain types of urinary retention. It focuses on easing the discomfort and risks associated with incomplete bladder emptying.


Restoring Voluntary Urination and Managing Atony

The medication is applied in clinical settings that involve acute or unstable symptom patterns, such as post-operative or post-partum urinary retention. It is also relevant in conditions characterized by periods of heightened symptoms, such as neurogenic bladder atony. It is relevant for easing symptoms related to physical discomfort and symptoms that create noticeable functional strain. The drug may assist with symptom clusters that may become intense or disruptive.

“This medication is considered relevant for easing symptoms that interfere with daily functioning.”

Quick Fact: Symptomatic Relief related to Incomplete Bladder Emptying

The medication helps manage the resulting symptoms, which may contribute to improved comfort during symptomatic periods and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview on Bethanechol

Eligibility and Restrictions for Use

Who Can and Cannot Use Myocholine?

Myocholine (bethanechol) is a prescription medicine primarily intended for adults to treat non-obstructive urinary retention. Its use is subject to numerous official regulatory restrictions and a long list of absolute contraindications.

Contraindicated and Restricted Use

Classification Population or Condition
Contraindicated Hypersensitivity to the drug; mechanical obstruction of the urinary or gastrointestinal (GI) tracts; any condition where the integrity of the GI or bladder wall is in doubt (e.g., recent surgery, peptic ulcer); and numerous pre-existing conditions including bronchial asthma, hyperthyroidism, epilepsy, Parkinson's disease, and certain cardiac conditions (e.g., bradycardia, hypotension, coronary artery disease).
Not Recommended Children and adolescents under 18 years old, as safety and effectiveness have not been established. Use in older patients requires caution due to a higher potential for adverse effects.
Pregnancy/Lactation Pregnancy Category C. Should only be used if clearly needed after weighing the potential risks and benefits. Not recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Myocholine's official interaction profile is defined primarily by pharmacodynamic outcomes. Regulatory documentation notes a risk of Antagonism when co-administered with Anticholinergic drugs, such as atropine, quinidine, or procainamide, which may counteract the intended therapeutic effect. Conversely, combining Myocholine with other Cholinergic drugs or Cholinesterase Inhibitors carries a risk of Additive Effects that can result in enhanced, potentially toxic, cholinergic activity.

A specific high-risk interaction is documented with Ganglion Blocking Compounds (like mecamylamine), where co-administration may lead to a critical fall in blood pressure and requires special care. Beta-Blockers are also noted for potentially enhancing adverse effects, specifically increasing the risk of cardiac conduction abnormalities.

Regulatory labeling addresses administration constraints with a Timing-Based Rule concerning food. Oral tablets must be taken one hour before or two hours after meals to avoid gastrointestinal adverse effects. No specific pharmacokinetic interactions involving CYP enzymes or transporters are officially documented, as regulatory sources state the drug's metabolic pathway is not fully elucidated. Additionally, co-administration with the herbal product Ginkgo biloba may increase the overall risk or severity of adverse effects.

Mechanism of Action

Myocholine (bethanechol chloride) functions as a direct-acting parasympathomimetic agent with high selectivity for muscarinic acetylcholine receptors (mAChRs) over nicotinic receptors. It acts as an agonist at these G protein-coupled receptors, particularly targeting M2 and M3 subtypes, which are prominent in smooth muscle tissues of the urogenital and gastrointestinal tracts.

Activation of the M3 mAChR, which is coupled to the Gq signaling protein, initiates the phospholipase C (PLC) pathway. PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate ( PIP2) into inositol 1,4,5-trisphosphate ( IP3) and diacylglycerol (DAG). Intracellular IP3 binds to its receptors on the sarcoplasmic reticulum, triggering the release of stored calcium ions ( Ca^2+) into the cytosol. The resulting increase in intracellular Ca^2+ concentration leads to the formation of the calcium-calmodulin complex, which subsequently activates myosin light chain kinase (MLCK). MLCK phosphorylates the myosin light chain, promoting the interaction of actin and myosin filaments. This intracellular cascade culminates in the contraction of smooth muscle fibers, specifically enhancing the tone of the detrusor muscle in the bladder and stimulating peristalsis and motility in the gastrointestinal tract.

Dosage and Administration Information

Administration Routes and Dosage Forms

Myocholine (Bethanechol Chloride) is administered via two primary, officially approved routes: the oral route as a tablet and the subcutaneous route as a solution for injection. The injectable solution must be used strictly for subcutaneous administration and is prohibited from being given intravenously or intramuscularly. The tablets are provided in several strengths, including 5 mg, 10 mg, 25 mg, and 50 mg.


Official Dosing and Frequency Patterns

The administration of Myocholine requires individualization to determine the minimum effective dose. For oral use, this process involves giving an initial dose of 5 mg or 10 mg and repeating this amount at hourly intervals until a satisfactory response is observed, with the total single test dose not exceeding 50 mg. Once the effective dose is established, the usual adult maintenance regimen falls within the range of 10 mg to 50 mg, administered three or four times daily. The standard single subcutaneous dose is fixed at 5 mg.


Contextual Instructions for Use

A key instruction for oral administration is the timing relative to food intake. The tablet is preferably given on an empty stomach, meaning one hour before or two hours after meals. The effect of an oral dose typically lasts for approximately one hour. Following a subcutaneous injection, patients are required to be observed for 30 minutes to 1 hour. Furthermore, the safety and effectiveness of this medication have not been established in the pediatric population below the age of 12 years.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Myocholine

Evidence for Acute Postoperative and Postpartum Urinary Retention

This section summarizes the structure of clinical research that has examined Myocholine for the temporary, functional difficulty with urination following surgery or childbirth, when no physical obstruction is present. The evidence base includes both Randomized Controlled Trials (RCTs) and observational studies. Researchers monitored outcomes related to functional imbalance, such as the volume of Post-Void Residual Urine (PVRU) and the frequency of requiring catheterization.

In specific adult populations, some trials reported measurements of catheterization needs. However, other large studies reported findings were mixed or that the difference in outcomes was not significant compared to control groups. This context is noted in regulatory documents, though evidence quality remains variable. There is limited information comparing the outcomes of the oral tablet versus the subcutaneous injection solution for this specific condition.

Evidence for Neurogenic Atony of the Bladder with Retention

This part reviews the research base that evaluated Myocholine’s use in patients with bladder muscle weakness stemming from nervous system conditions. The research examined functional measures and activity levels of the detrusor muscle, often through specific urodynamic changes, such as measuring Intravesical Pressure.

Research describes patterns related to bladder pressure, with some studies indicating that the measurements of muscle activity may be dependent on the specific type and severity of nerve damage. In some patient measurements, a detrusor contraction was not observed during the study period. The evidence base highlights that observed activity is often dependent on specific patient pathology, and the findings were mixed regarding the drug’s predictability across all neurogenic conditions.

What Remains Unclear or Inconsistent in the Evidence

The evidence base highlights several areas where certainty remains low. Trial Consistency shows that findings from RCTs for acute urinary retention have been mixed, creating inconsistent results. For generalized, non-acute retention, the use is associated with mixed findings and remains insufficiently studied by contemporary large-scale research. Furthermore, long-term effects are not fully established, and data for the pediatric population remain insufficient, with effectiveness and safety not established.

Key Studies & References

  1. Bethanechol - StatPearls - NCBI Bookshelf (Overview of Indications, Mechanism, and Contraindications)
  2. Underactive Bladder: Review of Progress and Impact From the International CURE-UAB Initiative (Discussion of Detrusor Underactivity Evidence)

Frequently Asked Questions (FAQ)

Common questions about Myocholine (FAQ)


Q: What is the main reason Myocholine is prescribed?

Myocholine is prescribed to address issues with the bladder. The FDA-approved indications state that it is used to treat nonobstructive urinary retention, which is difficulty in emptying the bladder. This condition can occur following surgery or childbirth, or due to a nerve-related issue known as neurogenic atony.


Q: What are the most commonly reported side effects of Myocholine?

Official product information describes common side effects primarily related to fluid changes. These often include sweating, increased salivation, and flushing of the skin. Gastrointestinal issues such as abdominal discomfort, cramps, nausea, and diarrhea are also frequently reported.


Q: Does taking Myocholine cause drowsiness or affect my ability to drive?

Regulatory documents do not explicitly list drowsiness as a primary side effect, but they do mention the possibility of dizziness, lightheadedness, and blurred vision. Because these effects could potentially impair coordination, the drug's warnings indicate that the ability to drive or operate machinery may be affected.


Q: Can Myocholine be used by children, or is it only for adults?

Since the effectiveness and safety of Myocholine have not been established through regulatory studies in pediatric patients, official information does not support its use in children. Therefore, its use is generally focused on the adult population.


Q: How long does it typically take before I might notice a change after starting Myocholine?

Studies and official information indicate that Myocholine generally works quickly after oral administration. Effects on the urinary and gastrointestinal tracts often begin within 30 minutes. The peak effect usually occurs approximately 60 to 90 minutes after taking the dose.


Q: Can elderly patients use Myocholine without special precautions?

Official regulatory guidance states that the use of Myocholine in older patients requires caution. This is due to the potential for adverse effects such as flushing, vomiting, and diarrhea, as well as possible limitations in effectiveness compared to younger adults.


Q: Does Myocholine interact with alcohol?

Official warnings indicate that combining Myocholine with alcohol may increase the risk of certain side effects. Specifically, consuming alcohol may worsen effects like dizziness while taking this medication.


Q: Does Myocholine affect blood pressure?

Yes, Myocholine can affect blood pressure. Regulatory documents note that the drug may cause a drop in blood pressure, a condition known as hypotension. Orthostatic hypotension, which is dizziness that occurs when standing up, is also a reported side effect, particularly when treatment is first started.


Q: Are there any serious side effects associated with Myocholine that I should know about?

Regulatory warnings highlight the potential for serious adverse events, such as signs of bronchospasm (difficulty breathing, wheezing, or tightness in the chest). The potential for a sudden, severe drop in blood pressure is another serious complication noted in regulatory materials.


Q: If I am pregnant or breastfeeding, can I use Myocholine?

Myocholine is assigned FDA Pregnancy Category C, which means that the drug should be used only after careful consideration of the potential risks and benefits. Official guidance notes that it is not known whether the drug passes into breast milk during breastfeeding, and therefore caution is indicated.


Q: Is there a generic version of Myocholine available?

Yes, the drug is available in a generic form. Myocholine is a trade name for the substance bethanechol chloride, which is widely available from various manufacturers.


Q: What kind of patient is generally eligible for Myocholine treatment?

Patient eligibility is determined by the approved use, which is for nonobstructive urinary retention. This eligibility is further defined by the contraindications, as regulatory documents specify that the drug is contraindicated for use in patients with conditions like hyperthyroidism, active peptic ulcers, or asthma.


Q: How is the mechanism of Myocholine described in official documents?

Myocholine is described in official documents as acting as a cholinergic agent. Its mechanism involves directly stimulating muscarinic receptors, which causes the main muscle of the bladder (the detrusor muscle) to contract more strongly, assisting with urination.


Q: Why do official documents mention specific patient groups should avoid Myocholine?

Official documents list the conditions under which Myocholine must not be used (contraindicated). These prohibitions are in place due to the risk of serious complications for patients with conditions such as hyperthyroidism, asthma, severe heart conditions (like bradycardia), active peptic ulcers, or obstruction in the GI tract or bladder neck.


Q: Are there any known drug-disease interactions with Myocholine (e.g., for people with diabetes)?

Official information outlines known drug-disease interactions where the drug’s use is restricted or contraindicated. Conditions like peptic ulcer, hyperthyroidism, asthma, seizure disorders, and Parkinsonism are listed as regulatory precautions.


Q: Is it common for Myocholine to cause stomach upset?

Yes, stomach upset is commonly associated with this medication. Regulatory documentation lists gastrointestinal side effects such as diarrhea, nausea, vomiting, and stomach cramps as common occurrences.


Q: Where can I find the official prescribing information for Myocholine?

Official prescribing information is available through government-hosted resources. Authoritative sources like DailyMed, which hosts the most up-to-date FDA label, or other governmental health authority websites are the official locations for this complete documentation.


Q: What types of drug interactions are generally described for Myocholine?

Regulatory labels describe general classes of drugs that interact with Myocholine. These include anticholinergic medicines (used for conditions like motion sickness or Parkinson's) and ganglion-blocking agents, which when combined, carry a risk of severe drops in blood pressure.


Q: How is the safety of Myocholine classified by regulatory bodies?

Regulatory bodies classify the drug’s safety for specific situations, such as pregnancy. The FDA classifies the safety of Myocholine during pregnancy as Category C.


Q: Can Myocholine be taken on an empty stomach?

Official guidelines for administration state that Myocholine is to be taken on an empty stomach. The product information specifies this generally means taking the medication one hour before or two hours after eating food.


Q: What is the average duration of the drug's effect after one administration?

According to official pharmacological information, the effect of an oral therapeutic dose typically lasts for approximately one hour. This indicates a relatively short duration of action.


Q: Are there any warnings about the use of Myocholine in patients with glaucoma?

Official warnings note the potential for systemic vagotonic effects. The drug is contraindicated in patients with conditions such as hyperthyroidism and asthma, and the potential for these systemic effects means that use in other conditions may require regulatory caution.


Q: Is there a specific drug class that Myocholine belongs to?

Myocholine, which is chemically known as bethanechol chloride, is classified by regulatory documents as a parasympathomimetic agent. This means it works by mimicking certain effects of the parasympathetic nervous system, specifically as a cholinergic agent.


Q: Do I need to take Myocholine at a specific time of day?

Official guidelines state that the drug is to be taken three or four times daily on an empty stomach. The product information does not specify a particular clock time like morning or night, focusing instead on the required frequency and relation to meals.


Q: What are the non-directive guidelines for use conditions for Myocholine?

Official use conditions include the requirement that the oral drug be taken on an empty stomach. Furthermore, regulatory instructions prohibit administering the injectable form intravenously (into a vein) or intramuscularly (into a muscle).


Q: Is Myocholine recommended for people with heart conditions?

No, the drug is contraindicated for use in people with certain heart conditions. Official drug labels list both coronary artery disease and slow heart rate (bradycardia) as contraindications, meaning the drug is prohibited due to its potential effects on the cardiovascular system.

How should Myocholine be stored and disposed of?

Storage and Disposal of Myocholine (Bethanechol Chloride)

Myocholine tablets must be stored according to specific conditions defined in regulatory labeling to ensure product stability.

Official Storage Requirements

The medication must be stored at Controlled Room Temperature, which is defined as 20^circC to 25^circC (68^circF to 77^circF). Storage must strictly avoid freezing and excessive heat. To maintain stability, the tablets must be protected from moisture and stored in a tight, light-resistant container.

Condition Requirement
Temperature 20^circC to 25^circC (68^circF to 77^circF)
Environmental Protect from moisture; do not freeze
Container Tight, light-resistant container

Handling and Disposal

For safety, Myocholine must be kept out of the reach of children, utilizing a child-resistant closure on the container. Unused or expired medication must be disposed of in accordance with applicable local, state, and federal laws and regulations. Regulatory guidelines advise against discarding the product into drains or the sewage system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Myocholine found in:

A-Z Index: